Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) — Tangible Net Worth Ratio

Latest as of June 2026: 84.5%

Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a Tangible Net Worth Ratio of 84.5% as of June 2026. This metric is calculated by deducting intangible assets (CN¥480.28 Million) from net assets (CN¥3.10 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Sinopep-Allsino Biopharmaceutical Co. Lt (688076) equity growth momentum to track the company's year-over-year net asset growth rate.

Tangible NW Ratio

84.5%
Tangible equity / total equity

Net Assets (Equity)

CN¥3.10 Billion
CNY

Intangible Assets

CN¥480.28 Million
Goodwill, patents, brand value

Total Assets

CN¥7.07 Billion
CNY

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Tangible Net Worth Ratio (2013–2025)

This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's Tangible Net Worth Ratio has changed across 12 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 84.5%, reflecting net assets of CN¥3.10 Billion with intangible assets of CN¥480.28 Million CNY. For live market cap and overall valuation, see Sinopep-Allsino Biopharmaceutical Co. Lt stock valuation.

Annual Tangible Net Worth Ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2025)

The table below presents the year-by-year Tangible Net Worth Ratio for Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2025, covering 12 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore capital reinvestment ratio of Sinopep-Allsino Biopharmaceutical Co. Lt to see what proportion of operating cash flow is directed to capital expenditures.

Year Tangible NW Ratio Net Assets (CNY) Intangible Assets Total Assets Change (pp)
2025 84.9% CN¥3.00 Billion CN¥453.57 Million CN¥6.74 Billion ▼ -4.8 pp
2024 89.7% CN¥2.68 Billion CN¥275.43 Million CN¥5.08 Billion ▼ -3.8 pp
2023 93.5% CN¥2.19 Billion CN¥142.54 Million CN¥3.55 Billion ▲ +0.3 pp
2022 93.2% CN¥1.92 Billion CN¥131.41 Million CN¥2.52 Billion ▼ -1.4 pp
2021 94.6% CN¥1.81 Billion CN¥97.79 Million CN¥2.13 Billion ▲ +4.1 pp
2020 90.4% CN¥966.02 Million CN¥92.32 Million CN¥1.40 Billion ▲ +1.1 pp
2019 89.4% CN¥838.98 Million CN¥89.12 Million CN¥1.24 Billion ▲ +0.6 pp
2018 88.8% CN¥785.38 Million CN¥88.20 Million CN¥1.05 Billion ▲ +11.7 pp
2017 77.0% CN¥321.20 Million CN¥73.77 Million CN¥611.47 Million ▲ +33.7 pp
2016 43.3% CN¥34.95 Million CN¥19.82 Million CN¥160.11 Million ▼ -17.0 pp
2015 60.3% CN¥73.32 Million CN¥29.11 Million CN¥196.67 Million ▲ +588.9 pp
2013 -528.6% CN¥3.69 Million CN¥23.17 Million CN¥166.81 Million
pp = percentage points